{"prompt": "['Committee.-A interim analysis will be conducted to support a planned regulatory filing for FDC,', 'which will consist of a subset of the analyses planned for the primary analysis. The results of this', \"interim analysis will be evaluated by a Sponsor's Internal Monitoring Committee. Further details\", 'will be specified in the Statistical Analysis Plan.', '7.', 'DATA COLLECTION AND MANAGEMENT', '7.1', 'DATA QUALITY ASSURANCE', 'A contract research organization (CRO) will be responsible for the data management of this', 'study, including quality checking of the data. Data entered manually will be collected via', 'EDC through use of eCRFs. Sites will be responsible for data entry into the EDC system. In', 'the event of discrepant data, the CRO will request data clarification from the sites, which the', 'sites will resolve electronically in the EDC system.', 'The Sponsor will perform oversight of the data management of this study. The CRO will', \"produce eCRF Specifications for the study based on Sponsor's templates including quality\", 'checking to be performed on the data.', \"Electronic CRFs and correction documentation will be maintained in the EDC system's audit\", 'trail. System backups for data stored by the Sponsor and records retention for the study', \"data will be consistent with the Sponsor's standard procedures.\", 'PRO and HCP reported outcomes data will be collected on paper questionnaires. Study site', 'staff will enter these data into the EDC system. Paper copies of each questionnaire are', 'source documents (see Section 7.3) and will be maintained at the study site.', '7.2', 'ELECTRONIC CASE REPORT FORMS', 'Electronic CRFs are to be completed through use of a Sponsor-designated EDC system.', 'Sites will receive training and have access to a manual for appropriate eCRF completion.', 'Electronic CRFs will be submitted electronically to the Sponsor and should be handled in', 'accordance with instructions from the Sponsor.', 'All eCRFs should be completed by designated, trained site staff. eCRFs should be reviewed', 'and electronically signed and dated by the investigator or a designee.', 'At the end of the study, the investigator will receive patient data for his or her site in a', 'readable format that must be kept with the study records. Acknowledgement of receipt of', 'the data is required.', '7.3', 'SOURCE DATA DOCUMENTATION', 'Study monitors will perform ongoing source data verification and review to confirm that', 'critical protocol data (i.e., source data) entered into the eCRFs by authorized site personnel', 'are accurate, complete, and verifiable from source documents.', 'Source documents (paper or electronic) are those in which patient data are recorded and', 'documented for the first time. They include, but are not limited to, hospital records, clinical', 'and office charts, laboratory notes, memoranda, patient reported outcomes, evaluation', 'checklists, pharmacy dispensing records, recorded data from automated instruments,', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '85 / Protocol MO40628, Version 12']['copies of transcriptions that are certified after verification as being accurate and complete,', 'microfiche, photographic negatives, microfilm or magnetic media, X-rays, patient files, and', 'records kept at pharmacies, laboratories, and medico-technical departments involved in a', 'clinical trial.', 'Before study initiation, the types of source documents that are to be generated will be clearly', 'defined in the Trial Monitoring Plan. This includes any protocol data to be entered directly', 'into the eCRFs (i.e., no prior written or electronic record of the data) and considered source', 'data.', 'Source documents that are required to verify the validity and completeness of data entered', 'into the eCRFs must not be obliterated or destroyed and must be retained per the policy for', 'retention of records described in Section 7.5.', 'To facilitate source data verification and review, the investigators and institutions must', 'provide the Sponsor direct access to applicable source documents and reports for', 'trial-related monitoring, Sponsor audits, and IRB/EC review. The study site must also allow', 'inspection by applicable health authorities.', '7.4', 'USE OF COMPUTERIZED SYSTEMS', \"When clinical observations are entered directly into a study site's computerized medical\", 'record system (i.e., in lieu of original hardcopy records), the electronic record can serve as', 'the source document if the system has been validated in accordance with health authority', 'requirements pertaining to computerized systems used in clinical research. An acceptable', 'computerized data collection system allows preservation of the original entry of data. If', 'original data are modified, the system should maintain a viewable audit trail that shows the', 'original data as well as the reason for the change, name of the person making the change,', 'and date of the change.', '7.5', 'RETENTION OF RECORDS', 'Records and documents pertaining to the conduct of this study and the distribution of IMP,', 'including eCRFs, paper PRO and HCP reported outcome data, Informed Consent Forms,', 'laboratory test results, and medication inventory records, must be retained by the Principal', 'Investigator for at least 15 years after completion or discontinuation of the study or for the', 'length of time required by relevant national or local health authorities, whichever is longer.', 'After that period of time, the documents may be destroyed, subject to local regulations.', 'No records may be disposed of without the written approval of the Sponsor. Written', 'notification should be provided to the Sponsor prior to transferring any records to another', 'party or moving them to another location.', '8.', 'ETHICAL CONSIDERATIONS', '8.1', 'COMPLIANCE WITH LAWS AND REGULATIONS', 'This study will be conducted in full conformance with the ICH E6 guideline for Good Clinical', 'Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the', 'country in which the research is conducted, whichever affords the greater protection to the', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '86 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}